Total Payments
$131,409
2024 Payments
$2,107
Companies
12
Transactions
101
Medicare Patients
531
Medicare Billing
$51,421
Payment Breakdown by Category
Consulting$90,609 (69.0%)
Other$16,120 (12.3%)
Travel$14,956 (11.4%)
Research$7,402 (5.6%)
Food & Beverage$2,322 (1.8%)
Education$1.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $90,609 | 26 | 69.0% |
| Travel and Lodging | $14,956 | 36 | 11.4% |
| Honoraria | $9,450 | 3 | 7.2% |
| Unspecified | $7,402 | 2 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,670 | 1 | 5.1% |
| Food and Beverage | $2,322 | 32 | 1.8% |
| Education | $1.00 | 1 | 0.0% |
Payments by Type
General
$124,007
99 transactions
Research
$7,402
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $43,186 | 27 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $36,590 | 36 | $0 (2021) |
| PFIZER INC. | $17,035 | 7 | $0 (2022) |
| UCB, Inc. | $7,384 | 6 | $0 (2024) |
| UCB SA | $6,140 | 2 | $0 (2021) |
| Janssen Biotech, Inc. | $5,237 | 6 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,120 | 4 | $0 (2017) |
| Lilly USA, LLC | $4,050 | 3 | $0 (2019) |
| Novartis Pharma AG | $3,528 | 2 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,758 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,107 | 7 | Janssen Scientific Affairs, LLC ($1,208) |
| 2022 | $9,949 | 8 | Janssen Biotech, Inc. ($5,237) |
| 2021 | $12,511 | 5 | PFIZER INC. ($6,750) |
| 2020 | $23,525 | 6 | Eli Lilly and Company ($11,500) |
| 2019 | $47,718 | 38 | Novartis Pharmaceuticals Corporation ($26,009) |
| 2018 | $27,189 | 23 | Eli Lilly and Company ($18,013) |
| 2017 | $8,409 | 14 | Novartis Pharmaceuticals Corporation ($4,175) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Eli Lilly and Company | TALTZ (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $59.84 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $4.31 | General |
| Category: Immunology | ||||||
| 08/27/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $134.95 | General |
| Category: Immunology | ||||||
| 07/02/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: Immunology | ||||||
| 06/27/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $120.52 | General |
| Category: Immunology | ||||||
| 06/11/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: Immunology | ||||||
| 12/06/2022 | Novartis Pharma AG | COSENTYX (Biological) | — | Cash or cash equivalent | $2,012.50 | Research |
| Study: SURPASS • Category: DERMATOLOGY | ||||||
| 10/11/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Immunology | ||||||
| 09/30/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $59.82 | General |
| Category: Immunology | ||||||
| 09/30/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $39.88 | General |
| Category: Immunology | ||||||
| 09/30/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 09/30/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 09/29/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $97.20 | General |
| Category: Immunology | ||||||
| 06/16/2022 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $2,700.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/22/2021 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $2,700.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/11/2021 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| 10/06/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| 08/15/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: IMMUNOLOGY | ||||||
| 01/08/2021 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $4,050.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| 09/16/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $5,750.00 | General |
| 07/03/2020 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,840.00 | General |
| 05/22/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| 02/19/2020 | Novartis Pharma AG | AIN457F_COSENTYX_IMMUNOLOGY (Biological) | Consulting Fee | Cash or cash equivalent | $1,515.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,389 | 1 |
| SURPASS | Novartis Pharma AG | $2,013 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 134 | 233 | $73,251 | $13,859 |
| 2022 | 4 | 132 | 195 | $62,555 | $12,305 |
| 2021 | 2 | 114 | 166 | $55,350 | $13,189 |
| 2020 | 4 | 151 | 197 | $60,016 | $12,068 |
Total Patients
531
Total Services
791
Medicare Billing
$51,421
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 75 | 162 | $44,470 | $8,577 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 19 | 19 | $11,647 | $2,145 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 28 | $11,319 | $2,138 | 18.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2023 | 16 | 24 | $5,815 | $998.63 | 17.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 69 | 126 | $33,936 | $6,814 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 32 | 32 | $17,600 | $3,320 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 17 | $6,774 | $1,308 | 19.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2022 | 14 | 20 | $4,245 | $862.35 | 20.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 43 | 72 | $22,680 | $5,719 | 25.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 40 | 63 | $14,170 | $3,569 | 25.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 18 | 18 | $9,621 | $2,020 | 21.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $8,879 | $1,881 | 21.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 63 | $19,072 | $3,712 | 19.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 48 | 67 | $13,768 | $2,642 | 19.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 13 | 13 | $8,762 | $1,867 | 21.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 15 | 15 | $7,764 | $1,698 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 14 | $4,424 | $780.88 | 17.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 11 | $3,355 | $743.08 | 22.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 13 | 14 | $2,871 | $624.89 | 21.8% |
About Dr. Joerg Ermann, MD
Dr. Joerg Ermann, MD is a Rheumatology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1629197736.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joerg Ermann, MD has received a total of $131,409 in payments from pharmaceutical and medical device companies, with $2,107 received in 2024. These payments were reported across 101 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($90,609).
As a Medicare-enrolled provider, Ermann has provided services to 531 Medicare beneficiaries, totaling 791 services with total Medicare billing of $51,421. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Boston, MA
- Active Since 03/28/2007
- Last Updated 12/19/2019
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629197736
Products in Payments
- COSENTYX (Biological) $37,831
- TALTZ (Drug) $22,046
- XELJANZ (Drug) $17,035
- Cimzia (Drug) $7,380
- TREMFYA (Drug) $6,445
- Entyvio (Biological) $4,120
- AIN457F_COSENTYX_IMMUNOLOGY (Biological) $1,515
- Humira (Biological) $114.22
- RINVOQ (Biological) $59.84
- Bimzelx (Biological) $4.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Boston
Lee Simon, M.d, M.D
Rheumatology — Payments: $917,853
Rheumatology $917,853
Michael Weinblatt, Md, MD
Rheumatology — Payments: $408,548
Rheumatology $408,548
Sebastian Unizony, Md, MD
Rheumatology — Payments: $172,168
Rheumatology $172,168
Jack Bukowski, Md Phd, MD PHD
Rheumatology — Payments: $153,965
Rheumatology $153,965
Michael Brenner, Md, MD
Rheumatology — Payments: $141,423
Rheumatology $141,423
Robert Lafyatis
Rheumatology — Payments: $119,295
Rheumatology $119,295